US Surgical completes Valleylab acquisition and boosts research and development
This article was originally published in Clinica
Executive Summary
Net income for US Surgical in the first-quarter was $25 million, compared with $30 million in the previous quarter, despite a growth in sales of 11% to reach $317 million. During the quarter the company completed the integration of Valleylab, which it bought from Pfizer. US Surgical claims the acquisition has positioned it as the world leader in electrosurgical and ultrasonic product sales.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.